AMY 106
Alternative Names: AMY-106Latest Information Update: 20 Dec 2022
At a glance
- Originator Amyndas Pharmaceuticals
- Class Anti-inflammatories; Eye disorder therapies; Peptides
- Mechanism of Action Complement C3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Age-related macular degeneration
Most Recent Events
- 20 Dec 2022 Pharmacodynamics data from preclinical studies in Age-related macular degeneration released by Amyndas pharmaceuticals pipeline, December 2022)
- 21 Sep 2022 Preclinical trials in Age-related macular degeneration in USA (Intravitreous) before September 2022 (Amyndas pipeline, September 2022)
- 21 Sep 2022 Amyndas plans a phase I trial for Age-related macular degeneration (In volunteers) (Amyndas pipeline, December 2022)